Polypeptide-Polymer Conjugate Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stabilizing physiologically active polypeptides, such as insulin, face challenges in maintaining blood concentration and potency due to low stability and frequent administration requirements, with existing polymer conjugation methods often reducing drug potency and increasing production costs.
Innovation Solution
A method involving the covalent linking of physiologically active polypeptides with non-peptide polymers in a reaction solution containing an organic solvent to create a conjugate, which is then purified, enhancing the blood half-life and in vivo activity of the polypeptide while reducing production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEG is bound to protein drugs to increase stability, then protein stability and solubility are improved, but the potency of the physiologically active polypeptide is significantly lowered
Solution Approach 1:
The invention divides the modification process into two separate steps: first conjugating the non-peptide polymer to the carrier, then conjugating the physiologically active polypeptide to the polymer-carrier conjugate. This segmentation allows each step to be optimized independently, preventing the loss of polypeptide potency while achieving stability enhancement.
Solution Approach 2:
The non-peptide polymer acts as an intermediary between the carrier and the physiologically active polypeptide. By introducing this intermediate component, the invention enables stable conjugation without direct interaction between the polypeptide and carrier that would cause potency loss, thus resolving the contradiction between stability and potency.
2Object-affected harmful factors
If the molecular weight of PEG is increased to reduce binding yield, then the reactivity of PEG with proteins is lowered, but the binding yield decreases
Solution Approach 1:
The invention segments the conjugation process into distinct steps with the non-peptide polymer serving as an intermediate. This allows the use of lower molecular weight polymers with higher reactivity in the first step, achieving high binding yield, while the final polypeptide-conjugate maintains stability without requiring excessive reactivity.
Solution Approach 2:
The invention changes the molecular weight parameter of the non-peptide polymer to be lower than traditional high molecular weight PEG, which increases reactivity and binding yield in the first conjugation step, while the overall conjugate structure maintains stability through the carrier-polypeptide interaction.
3Reliability
If frequent injections are administered to maintain blood concentration, then the blood concentration and potency of protein medicines are maintained, but excessive suffering is caused to patients
Solution Approach 1:
The invention applies partial modification by conjugating the polypeptide to a carrier-polypeptide conjugate structure rather than fully modifying all polypeptide molecules. This partial conjugation approach provides sufficient stability enhancement to extend half-life and reduce injection frequency, while maintaining adequate potency for therapeutic effect.
Solution Approach 2:
The invention creates a composite structure combining the carrier, non-peptide polymer, and physiologically active polypeptide. This composite material integrates the stability benefits of the carrier-polypeptide conjugate with the biological activity of the polypeptide, achieving extended half-life that reduces injection frequency while maintaining therapeutic efficacy.
4Reliability
If the prior method of first conjugating carrier with non-peptide polymer is used, then the conjugate can be formed, but great expense is incurred
Solution Approach 1:
The invention inverts the conventional conjugation sequence by first conjugating the non-peptide polymer to the carrier, then conjugating the polypeptide to this intermediate. This reversed approach simplifies the overall process and reduces costs by enabling the use of more economical reagents and conditions in each step compared to direct polypeptide-carrier conjugation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high yield and purity of the polypeptide conjugate, significantly extending the blood half-life and maintaining in vivo activity, enabling the development of sustained-release formulations with reduced administration frequency and improved patient convenience.
Implementation Method 1
linking the physiologically active polypeptide with the non-peptide polymer through a covalent bond using an organic solvent
Data Source
AI summary
A method for preparing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using an organic solvent is provided. A method for preparing a physiologically active polypeptide complex by linking the conjugate with a carrier is provided. The complex shows improved in vivo duration and stability of the physiologically active polypeptide. The method can prepare the conjugate at a lower production cost, and the resulting conjugate shows an extension of in vivo activity at a relatively high level and significantly increase in the blood half-life.